STOCK TITAN

aiki - AIKI STOCK NEWS

Welcome to our dedicated page for aiki news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on aiki stock.

AIkido Pharma Inc., established in 1967, is a biotechnology company focusing on developing small-molecule anti-cancer therapeutics. The company leverages patented technology from leading universities and esteemed researchers to create an innovative drug platform. AIkido Pharma has forged significant partnerships with renowned institutions such as The University of Texas at Austin and Wake Forest University. The company's diverse pipeline includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Besides oncology, AIkido Pharma is expanding its portfolio to address unmet medical needs, including developing a broad-spectrum antiviral platform targeting viruses like Influenza, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus.

In recent news, AIkido Pharma has been active with its $2 million share repurchase program, showcasing commitment to shareholder value. The company also highlights its collaborations and achievements in the broader biotechnology landscape, aiming to bring groundbreaking treatments to market. Investors and stakeholders can follow the latest updates and developments as AIkido Pharma continues to enhance its therapeutic offerings and strengthen its market presence.

Rhea-AI Summary
Dominari Holdings Inc. CEO Kyle Wool appeared on Fox Business' 'The Claman Countdown' to discuss sectors with pre-IPO potential and investment opportunities. Dominari Securities is a boutique investment bank. Replay of the interview available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DatChat provides update on $2 million share repurchase program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
buyback
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Dominari Holdings Inc. (Nasdaq: DOMH) appointed George Way as Chief Financial Officer effective April 3, 2023. With over 30 years of experience in finance and accounting, Way is expected to drive the company's growth in financial services. He previously served as Director of Finance at Steward Partners, where he contributed to significant expansion. Under Way's leadership, Dominari aims to enhance operational excellence and shareholder value by creating a results-driven finance department. The company's mission focuses on creating wealth for stakeholders by leveraging emerging trends in the financial services sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

DatChat has announced the launch of Habytat, a photorealistic metaverse featuring AI-powered pets. These virtual pets will mimic real-life interaction, growing from puppies and kittens to adults as users care for them. Users will be able to select from four dog breeds and two cat breeds for the initial launch in Spring 2023. The platform enhances user engagement through tasks such as feeding, training, and cleaning their pets. The initiative aims to democratize access to the metaverse and create a fun, interactive environment for pet lovers. For participation in breed selection, visit Habytat.io/pets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Habytat, a metaverse platform by SmarterVerse Inc., a subsidiary of DatChat (NASDAQ: DATS), is launching early this spring, offering 200 artists complimentary virtual gallery spaces. This initiative aims to empower artists in showcasing and selling their work globally. The galleries will include technical support for digitizing physical art and integrating online sales, enhancing artists' online presence. Located in Habytat's Geniuz City, designed like Miami's Wynwood arts district, these galleries promote creativity and accessibility. Interested artists can apply through Habytat's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

DatChat (NASDAQ: DATS) has appointed Wachsman as the agency of record for its subsidiary, Habytat by SmarterVerse, aimed at enhancing user engagement in the metaverse. CEO Darin Myman emphasized the goal of making metaverse technology accessible to a broader audience. Wachsman is recognized for its expertise in promoting innovative technologies and has received accolades from various industry publications. DatChat focuses on secure messaging and user privacy, providing a private social network that allows users control over their messages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Dominari Holdings Inc. (Nasdaq: DOMH) has initiated a $2 million share repurchase program, with the first purchase of 4,000 shares at $3.1012 each completed on December 27, 2022. CEO Anthony Hayes emphasized that the stock is undervalued, aiming to enhance shareholder value through this program. The company plans to continue repurchasing shares based on market conditions and regulations. Dominari, transitioning to fintech, operates under its subsidiary, Dominari Financial Inc., while still developing its therapeutic portfolio through Aikido Labs, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
buyback
Rhea-AI Summary

AIkido Pharma Inc. has officially changed its name to Dominari Holdings Inc. and its ticker symbol from AIKI to DOMH, effective December 22, 2022. This decision was made during a board meeting on December 5, 2022. The rebranding aligns with the company's strategic shift from healthcare to financial services. Dominari is in the process of acquiring a registered broker-dealer and has allocated approximately $3.2 million towards this new subsidiary, Dominari Financial Inc., while also continuing to develop its existing therapeutic technology through AIkido Labs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of aiki (aiki)?

The market cap of aiki (aiki) is approximately 19.5M.

What is AIkido Pharma Inc.'s primary focus?

AIkido Pharma Inc. focuses on developing small-molecule anti-cancer therapeutics and broad-spectrum antiviral platforms.

What recent achievements has AIkido Pharma Inc. accomplished?

AIkido Pharma Inc. has advanced its therapeutic drug platform and initiated a $2 million share repurchase program.

Who are AIkido Pharma Inc.'s key partners?

The company has significant partnerships with The University of Texas at Austin and Wake Forest University.

What types of cancer therapies does AIkido Pharma Inc. develop?

AIkido Pharma Inc. develops therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

Is AIkido Pharma Inc. involved in antiviral research?

Yes, AIkido Pharma Inc. is developing a broad-spectrum antiviral platform targeting viruses such as Influenza, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus.

How does AIkido Pharma Inc. contribute to oncology research?

AIkido Pharma Inc. contributes by developing innovative small-molecule therapies and continually expanding its pipeline to address unmet medical needs in oncology.

What is the company's approach to enhancing shareholder value?

AIkido Pharma Inc. has initiated a $2 million share repurchase program as part of its efforts to enhance shareholder value.

How does AIkido Pharma Inc. utilize its partnerships?

The company leverages its partnerships to access cutting-edge research and technology from leading universities and researchers, enhancing its drug development platform.

What makes AIkido Pharma Inc.'s antiviral platform unique?

AIkido Pharma Inc.'s antiviral platform is designed to inhibit replication of multiple viruses, offering a versatile approach to antiviral treatment.

Where can I find the latest news about AIkido Pharma Inc.?

The latest news about AIkido Pharma Inc. can be found on their official website and major financial news platforms.

aiki

Nasdaq:AIKI

AIKI Rankings

AIKI Stock Data

19.53M
Payroll Services
Professional, Scientific, and Technical Services
Link
US
New York